This week, we will discuss the use of LLMs for the diagnosis of complex nephrology cases. Can AI help nephrologists nail the correct diagnosis?
MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.
This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.
SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in stable KTR.
Do #flozins behave the same in transplanted kidneys? Check out the VA by Janany Sabescumar
Los iSGLT2 han revolucionado la protección cardiorrenal, pero los trasplantados renales han quedado fuera de la historia. El ensayo INFINITI empieza a cerrar esa brecha. ¿Flozinaran igual los iSGLT2 en el riñón trasplantado? Revisa el resumen visual creado por Janany Sabescumar
El estudio post EMPA-KIDNEY, evaluó los efectos de la empagliflozina en pacientes con enfermedad renal crónica. Los hallazgos mostraron que este tratamiento no solo proporcionó beneficios cardiorrenales significativos durante la fase activa del estudio, sino que también mantuvo estos efectos positivos por hasta 12 meses después de la interrupción del tratamiento.
Revisa el resumen visual realizado por Oscar Durón y únete a la conversación en nuestro próximo #NephJC
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (Voors, Nature Medicine 2023)
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)
Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes (JAMA 2024)
If you missed the biggest NephJC of the year, at least read the highlights here.
If you only read one #TenTweetNephJC this year, make it this one.
— Nephrology Journal Club (@NephJC) November 22, 2022
EMPA-KIDNEY is one of those landmark trials it is worth knowing inside-out, but you can still rapidly catch up on the key findings & author tweetchat secrets in the thread below👇 pic.twitter.com/VL2u8BoCLw
